CTLA4 and neoplasm: These results are consistent with a previous study that used a syngeneic model to demonstrate that ERY974 shows significant antitumour efficacy even in LLC1/hGPC3 tumours, which are representative of non-inflamed tumours32 and where anti-PD-1, PD-L1, and CTLA4 antibodies failed to show efficacy15.